focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksValiRx Share News (VAL)

Share Price Information for ValiRx (VAL)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 3.10
Bid: 3.00
Ask: 3.20
Change: -0.10 (-3.13%)
Spread: 0.20 (6.667%)
Open: 3.20
High: 3.20
Low: 2.95
Prev. Close: 3.20
VAL Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TRADING UPDATES: Arecor Therapeutics wins patent approval in US

Wed, 23rd Mar 2022 20:53

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News:

----------

Hydrogen Utopia International PLC - London-based company specialising in turning non-recyclable mixed waste plastic into carbon-free fuels - Says it believes that building new waste plastic to energy plants could be "significant" in allowing local communities across Europe to lessen the impacts of the gas and energy supply crisis and the anticipated market changes brought about by ongoing sanctions against Russia and the reluctance to rely upon it as an energy supplier in the future.

----------

ValiRx PLC - Nuneaton, England-based drug development company - Reports it is progressing towards the completion of its proposed sub-licence of VAL201 to TheoremRx Inc. VAL201's primary indication is for prostate cancer, with potential further research & development in breast and ovarian cancer. Company says TheoremRx continues to make good progress with its financing but notes that current global macro-economic events have impacted the timelines. First payments to ValiRx are expected on or before the end of June.

----------

Arecor Therapeutics PLC - Essex, England-based biopharmaceutical company - Wins patent grant from US Patent & Trademark Office protecting novel formulations of the group's insulin products, AT247 and AT278. Chief Scientific Officer Jan Jezek says: "This recently granted US patent, the first within the group's comprehensive insulin IP strategy, is a significant milestone, and we will continue to strengthen our IP portfolio with additional patent applications already in progress."

----------

GENinCode PLC - Manchester-based genetic testing company - Collaborates with Indiana University School of Medicine on a study using its Cardio inCode-SCORE for the risk assessment of patients for onset of atherosclerotic cardiovascular disease.

----------

88 Energy Ltd - oil exploration company focused on Alaska - Reaches total depth of 7,334 feet at Merlin-2 well and ceases drilling. Company says all three target reservoirs at the well were penetrated with elevated gas readings. Adds observations of cutting samples have revealed oil shows over all targets. Wireline logging is due to commence shortly.

----------

i(x) Net Zero PLC - Jersey-based investment company focused on sustainability - Says portfolio company Context Labs has secures a multi-year partnership with energy company Williams Co Inc. Partnership for the deployment of its Immutably-based Decarbonization as a Service platform. The deployment of the enterprise data fabric solution will facilitate Williams' energy transition, i(x) explains.

----------

All Star Minerals PLC - Haywards Heath, England-based mining services investor - Appoints Jason Brewer as chief executive officer. Current CEO Ian Harebottle reverts to the position of non-executive director with immediate effect. Says restructuring has been driven by "recent developments in Europe".

----------

Panther Metals PLC - mineral exploration company focused on Canada - Notes announcement of Panther Metals Ltd, in which it has 37% holding, detailing "significant" reverse circulation drilling sample assay results. Results from the Coglia nickel cobalt project in Western Australia include: 21 metres at 1.34% nickel from 72 metres and 10 metres at 1.3% nickel from 62 metres. 18 of the 26 holes assayed return results above 0.5% nickel and 500 parts per million of copper. Once drilling is complete at Coglia the drill rig will move to the Eight Foot Well gold prospect, the company adds.

----------

Cohort PLC - Reading, England-based technology company - Says its German subsidiary ELAC Sonar has been awarded a contract to supply hydroacoustic equipment by Fassmer Shipyard, on behalf of the Federal Office of Bundeswehr Equipment, Information Technology and In-Service Support. Contract is worth EUR4 million and is expected to complete in the final quarter of 2023.

----------

Tern PLC - London-based investor focused on the internet of things - Notes that Wyld Networks AB has received a purchase order for its Wyld Connect internet of things module from an unnamed Brazilian company in the forestry sector. Tern holds 59% of Wyld Networks.

----------

Capital Metals PLC - London-based mineral sands explorer - Says IHC Mining is nearing the completion of the development study for the Eastern Minerals project in Sri Lanka. Capital Metals expects the final report by mid-April. Adds that drill samples from the project are continuing to be assayed by an independent laboratory but warns of backlogs. Company working with Sri Lankan government to secure industrial mining license but says timeline is beyond their control. Discussion regarding offtake and strategic party agreements continue.

----------

By Heather Rydings; heatherrydings@alliancenews.com

Copyright 2022 Alliance News Limited. All Rights Reserved.

More News
14 Jul 2016 08:50

ValiRx Receives Approval To Submit Application For Cancer Drug Trial

Read more
7 Jul 2016 07:50

ValiRx Sells TRAC Technology To Germany's Sovicell For EUR800,000

Read more
13 Jun 2016 15:02

UK Shareholder Meetings Calendar - Next 7 Days

Read more
7 Jun 2016 09:19

ValiRx Highlights Progress With VAL201 Lead Compound, VAL401 Venture

Read more
19 May 2016 15:44

ValiRx updates market on 'significant' 2015

(ShareCast News) - Lifesciences company ValiRx reported on a "significant year" on Thursday, talking up its capital restructure and technical advancements in the 2015 calendar year. The AIM-traded firm, which focuses on cancer therapeutics and diagnostics for personalised medicine, said its Phase I/

Read more
19 May 2016 10:29

ValiRx Loss Narrows As Progress Is Made On Cancer Compounds

Read more
19 May 2016 09:23

ValiRx Says ValiSeek Begins Manufacturing VAL401 For Clinical Trial

Read more
29 Apr 2016 07:50

ValiRx Says ValiSeek Gets US Patent For VAL401 In Adenocarcinoma

Read more
19 Apr 2016 14:45

ValiRx Shares Fall After Bracknor Converts GBP200,000 Of Loan Notes (ALLISS)

Read more
1 Apr 2016 14:28

ValiRx Receives Conversion Notice For GBP90,000 From Bracknor (ALLISS)

Read more
21 Mar 2016 08:29

ValiRx Strikes GBP4 Million Convertible Funding Deal With Bracknor (ALLISS)

Read more
17 Mar 2016 09:07

ValiRx Hires Consultancy Firm Burns McClellan To Boost US Profile

Read more
17 Feb 2016 13:04

ValiRx Raises Funds To Back Ongoing Drug Trials (ALLISS)

Read more
16 Feb 2016 13:17

ValiRx achieves success in latest VAL201 trial

(ShareCast News) - ValiRx was pressing ahead with the trial process for its VAL201 trial treatment on Tuesday, following positive results from the most recent tranche of test patients. The AIM-traded life science company, with a focus on cancer diagnostics and therapeutics for personalised medicine,

Read more
16 Feb 2016 09:16

ValiRx Says Final Dose Escalation For VAL201 Trials Approved

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.